1
|
Barr J, Walz A, Restaino AC, Amit M, Barclay SM, Vichaya EG, Spanos WC, Dantzer R, Talbot S, Vermeer PD. Tumor-infiltrating nerves functionally alter brain circuits and modulate behavior in a mouse model of head-and-neck cancer. bioRxiv 2024:2023.10.18.562990. [PMID: 37905135 PMCID: PMC10614955 DOI: 10.1101/2023.10.18.562990] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/02/2023]
Abstract
Cancer patients often experience changes in mental health, prompting an exploration into whether nerves infiltrating tumors contribute to these alterations by impacting brain functions. Using a male mouse model for head and neck cancer, we utilized neuronal tracing techniques and show that tumor-infiltrating nerves indeed connect to distinct brain areas via the ipsilateral trigeminal ganglion. The activation of this neuronal circuitry led to behavioral alterations represented by decreased nest-building, increased latency to eat a cookie, and reduced wheel running. Tumor-infiltrating nociceptor neurons exhibited heightened activity, as indicated by increased calcium mobilization. Correspondingly, the specific brain regions receiving these neural projections showed elevated cFos and delta FosB expression in tumor-bearing mice, alongside markedly intensified calcium responses compared to non-tumor-bearing counterparts. The genetic elimination of nociceptor neurons in tumor-bearing mice led to decreased brain Fos expression and mitigated the behavioral alterations induced by the presence of the tumor. While analgesic treatment successfully restored behaviors involving oral movements to normalcy in tumor-bearing mice, it did not have a similar therapeutic effect on voluntary wheel running. This discrepancy points towards an intricate relationship, where pain is not the exclusive driver of such behavioral shifts. Unraveling the interaction between the tumor, infiltrating nerves, and the brain is pivotal to developing targeted interventions to alleviate the mental health burdens associated with cancer.
Collapse
Affiliation(s)
- Jeffrey Barr
- Sanford Research, Cancer Biology and Immunotherapies Group, Sioux Falls, South Dakota, USA
| | - Austin Walz
- Sanford Research, Cancer Biology and Immunotherapies Group, Sioux Falls, South Dakota, USA
| | - Anthony C. Restaino
- Sanford Research, Cancer Biology and Immunotherapies Group, Sioux Falls, South Dakota, USA
- University of South Dakota, Sanford School of Medicine, Vermillion, SD, USA
| | - Moran Amit
- University of Texas, MD Anderson Cancer Center, Houston, TX, USA
| | - Sarah M. Barclay
- Sanford Research, Cancer Biology and Immunotherapies Group, Sioux Falls, South Dakota, USA
| | | | - William C. Spanos
- Sanford Research, Cancer Biology and Immunotherapies Group, Sioux Falls, South Dakota, USA
- University of South Dakota, Sanford School of Medicine, Vermillion, SD, USA
| | - Robert Dantzer
- University of Texas, MD Anderson Cancer Center, Houston, TX, USA
| | - Sebastien Talbot
- Queen’s University, Department of Biomedical and Molecular Sciences, Kingston, Ontario, Canada
| | - Paola D. Vermeer
- Sanford Research, Cancer Biology and Immunotherapies Group, Sioux Falls, South Dakota, USA
- University of South Dakota, Sanford School of Medicine, Vermillion, SD, USA
| |
Collapse
|
2
|
Beaudry AG, Law ML, Gilley-Connor KR, Buley H, Dungan CM, Nascimento CMC, Vichaya EG, Wiggs MP. Diet-induced obesity does not exacerbate cachexia in male mice bearing Lewis-lung carcinoma tumors. Am J Physiol Regul Integr Comp Physiol 2024; 326:R254-R265. [PMID: 38252513 DOI: 10.1152/ajpregu.00208.2023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2023] [Revised: 01/11/2024] [Accepted: 01/11/2024] [Indexed: 01/24/2024]
Abstract
Cachexia is a muscle-wasting syndrome commonly observed in patients with cancer, which can significantly worsen clinical outcomes. Because of a global rise in obesity, the coexistence of cachexia in obese individuals poses unique challenges, with the impact of excessive adiposity on cachexia severity and underlying pathophysiology not well defined. Understanding the interplay between cachexia and obesity is crucial for improving diagnosis and treatment strategies for these patients; therefore, the present study examined differences in cachexia between lean and obese mice bearing Lewis lung carcinoma (LLC) tumors. Nine-week-old, male C57Bl6J mice were placed on either a chow or a high-fat diet (HFD) for 9 wk. After the diet intervention, mice were inoculated with LLC or vehicle. Markers of cachexia, such as body and muscle loss, were noted in both chow and HFD groups with tumors. Tumor weight of HFD animals was greater than that of chow. LLC tumors reduced gastrocnemius, plantaris, and soleus mass, regardless of diet. The tibialis anterior and plantaris mass and cross-sectional area of type IIb/x fibers in the gastrocnemius were not different between HFD-chow, HFD-tumor, and chow-tumor. Using RNA sequencing (RNA-seq) of the plantaris muscle from chow-tumor and HFD-tumor groups, we identified ∼400 differentially expressed genes. Bioinformatic analysis identified changes in lipid metabolism, mitochondria, bioenergetics, and proteasome degradation. Atrophy was not greater despite larger tumor burden in animals fed an HFD, and RNA-seq data suggests that partial protection is mediated through differences in mitochondrial function and protein degradation, which may serve as future mechanistic targets.NEW & NOTEWORTHY This study provides timely information on the interaction between obesity and cancer cachexia. Lean and obese animals show signs of cachexia with reduced body weight, adipose tissue, and gastrocnemius muscle mass. There was not significant wasting in the tibialis anterior, plantaris, or fast twitch fibers in the gastrocnemius muscle of obese animals with tumors. RNA-seq analysis reveals that obese tumor bearing animals had differential expression of mitochondria- and degradation-related genes, which may direct future studies in mechanistic research.
Collapse
Affiliation(s)
- Anna G Beaudry
- Department of Health, Human Performance, and Recreation, Baylor University, Waco, Texas, United States
| | - Michelle L Law
- Department of Human Sciences and Design, Baylor University, Waco, Texas, United States
| | - Kayla R Gilley-Connor
- Department of Psychology and Neuroscience, Baylor University, Waco, Texas, United States
| | - Hailey Buley
- Department of Psychology and Neuroscience, Baylor University, Waco, Texas, United States
| | - Cory M Dungan
- Department of Health, Human Performance, and Recreation, Baylor University, Waco, Texas, United States
| | | | - Elisabeth G Vichaya
- Department of Psychology and Neuroscience, Baylor University, Waco, Texas, United States
| | - Michael P Wiggs
- Department of Health, Human Performance, and Recreation, Baylor University, Waco, Texas, United States
| |
Collapse
|
3
|
McCready RG, Gilley KR, Kusumo LE, Hall GM, Vichaya EG. Chronic Stress Exacerbates Hyperglycemia-Induced Affective Symptoms in Male Mice. Neuroimmunomodulation 2023; 30:302-314. [PMID: 37852199 PMCID: PMC10641805 DOI: 10.1159/000534669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/18/2023] [Accepted: 10/16/2023] [Indexed: 10/20/2023] Open
Abstract
INTRODUCTION Among chronically ill populations, affective disorders remain underdiagnosed and undertreated. A high degree of comorbidity exists between diabetes and affective disorders, particularly depression and anxiety. The mechanisms underlying stress-induced affective dysregulation are likely distinct from those induced by diabetes. A direct comparison between stress- and hyperglycemia-induced affective dysregulation could provide insight into distinct mechanistic targets for depression/anxiety associated with these different conditions. METHODS To this end, the present study used male C57BL/6J mice to compare the independent and combined behavioral and neuroinflammatory effects of two models: (1) unpredictable chronic mild stress and (2) pharmacologically induced hyperglycemia. RESULTS Streptozotocin-induced hyperglycemia was associated with a set of behavioral changes reflective of the neurovegetative symptoms of depression (i.e., reduced open field activity, reduced grooming, increased immobility in the forced swim task, and decreased marble burying), increased hippocampal Bdnf and Tnf expression, and elevations in frontal cortex Il1b expression. Our chronic stress protocol produced alterations in anxiety-like behavior and decreased frontal cortex Il1b expression. DISCUSSION While the combination of chronic stress and hyperglycemia produced limited additive effects, their combination exacerbated total symptom burden. Overall, the data indicate that stress and hyperglycemia induce different symptom profiles via distinct mechanisms.
Collapse
Affiliation(s)
- Riley G McCready
- Department of Psychology and Neuroscience, Baylor University, Waco, Texas, USA
| | - Kayla R Gilley
- Department of Psychology and Neuroscience, Baylor University, Waco, Texas, USA
| | - Laura E Kusumo
- Department of Psychology and Neuroscience, Baylor University, Waco, Texas, USA
| | - Grace M Hall
- Department of Psychology and Neuroscience, Baylor University, Waco, Texas, USA
| | - Elisabeth G Vichaya
- Department of Psychology and Neuroscience, Baylor University, Waco, Texas, USA
| |
Collapse
|
4
|
Vichaya EG, Darpolor JK, Gross PS, Molkentine JM, Vermeer DW, Vermeer PD, Lee JH, Taniguchi CM, Dantzer R. Associative learning contributes to the persistence of fatigue-like behavior in male mice in a model of cancer survivorship. Brain Behav Immun 2023; 107:296-304. [PMID: 36323360 PMCID: PMC10208403 DOI: 10.1016/j.bbi.2022.10.018] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/23/2022] [Revised: 10/15/2022] [Accepted: 10/23/2022] [Indexed: 11/06/2022] Open
Abstract
Persistent fatigue is a debilitating side effect that impacts a significant proportion of cancer survivors for which there is not yet an FDA-approved treatment. While certainly a multi-factorial problem, persistent fatigue could be due, in part, to associations learned during treatment. Therefore, we sought to investigate the role of associative learning in the persistence of fatigue using a preclinical model of cancer survivorship. For this purpose, we used a murine model of human papilloma virus-related head and neck cancer paired with a curative regimen of cisplatin-based chemoradiation in male C57BL/6J mice. Fatigue-like behavior was assessed by measuring variations in voluntary wheel running using a longitudinal design. Treatment robustly decreased voluntary wheel running, and this effect persisted for more than a month posttreatment. However, when wheels were removed during treatment, to minimize treatment-related fatigue, mice showed a more rapid return to baseline running levels. We confirmed that the delayed recovery observed in mice with continual wheel access was not due to increased treatment-related toxicity, in fact running attenuated cisplatin-induced kidney toxicity. Finally, we demonstrated that re-exposure to a treatment-related olfactory cue acutely re-instated fatigue. These data provide the first demonstration that associative processes can modulate the persistence of cancer-related fatigue-like behavior.
Collapse
Affiliation(s)
- Elisabeth G Vichaya
- Department of Psychology & Neuroscience, Baylor University, Waco, TX 76798, USA.
| | - Josephine K Darpolor
- Graduate School of Biomedical Sciences, The University of Texas Health Science Center, Houston, TX 77030, USA
| | - Phillip S Gross
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Jessica M Molkentine
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Daniel W Vermeer
- Cancer Biology Research Center, Sanford Research, Sioux Falls, SD 57104, USA
| | - Paola D Vermeer
- Cancer Biology Research Center, Sanford Research, Sioux Falls, SD 57104, USA
| | - John H Lee
- Avera Cancer Institute, 1000 E 23(rd) St., Sioux Falls, SD 57105, USA
| | - Cullen M Taniguchi
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Robert Dantzer
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| |
Collapse
|
5
|
Vichaya EG, Ford BG, Moltenkine JM, Taniguchi CM, Phillip West A, Dantzer R. Sex differences in the behavioral and immune responses of mice to tumor growth and cancer therapy. Brain Behav Immun 2021; 98:161-172. [PMID: 34418499 PMCID: PMC8511067 DOI: 10.1016/j.bbi.2021.08.225] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Revised: 07/29/2021] [Accepted: 08/14/2021] [Indexed: 10/20/2022] Open
Abstract
There is significant variability in the expression of cancer-related fatigue. Understanding the factors that account for this variation provide insight into the underlying mechanisms. One important, but often overlooked, variable is biological sex. While a few clinical studies have indicated that female patients report higher levels of fatigue, these studies are subject to potential socio-culture reporting biases. Only a limited number of preclinical studies have considered sex differences in animal model of fatigue and few have simultaneously considered both disease- and treatment-related factors. The present series of studies was initiated to address the current knowledge gap on the importance of sex differences in cancer-related fatigue. We selected a murine model of human papilloma virus-positive head and neck cancer based on heterotypic injection of the mEERL95 cell line that grows in both male and female mice and responds to a regimen of cisplatin plus irradiation. We also tested the impact of immunotherapy treatment targeting PD1. Voluntary wheel running was used to evaluate fatigue-like behavior. Male mice grew larger tumors than did female mice and showed more severe fatigue-like behavior. We confirmed that the tumor increased the expression of inflammatory cytokines in the liver, but no sex differences were observed. As a trend toward elevated Cd3 mRNA was observed in female mice, we tested the importance of T cells using female Rag2-/- mice. The Rag2-/- female mice had accelerated tumor growth and more severe fatigue-like behavior. In response to cisplatin alone non-tumor-bearing female mice showed a slower recovery of wheel running activity compared to males. However, in response to chemoradiation and anti-PD1 neutralizing antibody, tumor-bearing female mice showed a better tumor response to therapy than male mice, but no significant sex differences were observed for wheel running. These findings point to different mechanisms underlying tumor- and treatment-induced behavioral fatigue and indicate that the sex factor can intervene to modulate the expression of fatigue-like behavior in particular circumstances.
Collapse
Affiliation(s)
- Elisabeth G Vichaya
- Department of Psychology & Neuroscience, Baylor University, Waco, TX 76798, United States
| | - Bianca G Ford
- Department of Symptom Research, MD Anderson Cancer Center, Houston, TX 77030, United States
| | - Jessica M Moltenkine
- Department of Experimental Radiation Oncology, MD Anderson Cancer Center, Houston, TX 77030, United States
| | - Cullen M Taniguchi
- Department of Experimental Radiation Oncology, MD Anderson Cancer Center, Houston, TX 77030, United States
| | - A Phillip West
- Department of Microbial Pathogenesis and Immunology, College of Medicine, Texas A&M University, Bryan, TX 77087, United States
| | - Robert Dantzer
- Department of Symptom Research, MD Anderson Cancer Center, Houston, TX 77030, United States.
| |
Collapse
|
6
|
Casaril AM, Vichaya EG, Rishi MR, Ford BG, Dantzer R. Lipopolysaccharide does not alter behavioral response to successive negative contrast in mice. Psychopharmacology (Berl) 2021; 238:691-697. [PMID: 33410982 PMCID: PMC8075575 DOI: 10.1007/s00213-020-05721-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/01/2020] [Accepted: 11/13/2020] [Indexed: 11/26/2022]
Abstract
BACKGROUND Reduced motivation is one of the main symptomatic features of inflammation-induced depression. However, the exact nature of inflammation-induced alterations in motivation remains to be fully defined. As inflammation has been shown to increase sensitivity to negative stimuli, the present series of experiments was initiated to determine whether systemic inflammation induced by infra-septic doses of lipopolysaccharide (LPS) in mice influences consummatory and instrumental responding to successive negative contrast. METHODS Successive negative contrast was operationally defined by a shift to a lower value reward than the one mice were trained with. Mice were trained to drink a high sucrose concentration solution and exposed to an acute shift to a lower concentration of sucrose. In another series of experiments, mice were trained to nose poke for chocolate pellets according to a fixed reinforcement schedule 10 (10 nose pokes for the food reinforcement) and exposed to a shift to a lower reward value (decreased number of chocolate pellets or replacement of chocolate pellets by less preferred grain pellets). Lipopolysaccharide (LPS) was administered at the dose of 0.33 1 mg/kg 24 h before the shift. RESULTS Mice trained to drink a high sucrose concentration responded to the shift in reward value by a reduction in the volume of sucrose consumed and a decrease in lick numbers and bout durations. Mice trained to nose poke for chocolate pellets responded to the shift by alterations in their total number of nose pokes. In both conditions, LPS had no consistent effect on the response to the shift in reward value. CONCLUSIONS These findings indicate a high variability in the effects of LPS on successive negative contrast and fail to provide evidence in favor of the hypothesis that LPS increases sensitivity to decreases in expected rewards.
Collapse
Affiliation(s)
- Angela M Casaril
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX, 77030, USA
- Neurobiotechnology Research Group, Federal University of Pelotas, Pelotas, Rio Grande do Sul, 96160-000, Brazil
| | - Elisabeth G Vichaya
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX, 77030, USA
- Department of Psychology & Neuroscience, Baylor University, Waco, TX, 76798, USA
| | - M Raafay Rishi
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX, 77030, USA
| | - Bianca G Ford
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX, 77030, USA
| | - Robert Dantzer
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX, 77030, USA.
| |
Collapse
|
7
|
Vichaya EG, Ford BG, Quave CB, Rishi MR, Grossberg AJ, Dantzer R. Toll-like receptor 4 mediates the development of fatigue in the murine Lewis Lung Carcinoma model independently of activation of macrophages and microglia. Psychoneuroendocrinology 2020; 122:104874. [PMID: 32979744 PMCID: PMC7686070 DOI: 10.1016/j.psyneuen.2020.104874] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/28/2020] [Revised: 06/23/2020] [Accepted: 09/07/2020] [Indexed: 12/14/2022]
Abstract
Cancer-related fatigue at the time of tumor diagnosis is commonly attributed to inflammation associated with the disease process. However, we have previously demonstrated that running wheel deficits occur well before increased expression of proinflammatory cytokines in the liver and brain in a murine model of human papilloma virus-related head and neck cancer (mEER). Further, we have demonstrated that genetic deletion of type I interleukin-1 receptor and MyD88 has no effect. In the current investigation we sought to test the generality of this finding by assessing whether there is a role for toll-like receptor (TLR) 4-dependent inflammation in the fatigue-like behavior observed in mice with Lewis Lung Carcinoma (LLC) or mEER tumors. Genetic deletion of TLR4 attenuated tumor-induced elevations in liver pro-inflammatory cytokine expression in both models. However, it only abrogated wheel running deficits in LLC tumor bearing mice. To determine whether TLR4 signaling in the LLC model involves innate immune cells, mice were treated with the colony stimulating factor (CSF)-1 receptor antagonist PLX-5622 before and throughout tumor development to deplete microglia and peripheral macrophages. Administration of PLX-5622 had no protective effect on wheel running deficits in either mEER or LLC tumor models despite effective depletion of microglia and a down regulation of peripheral proinflammatory cytokine expression. These results indicate that the TLR4 signaling that mediates fatigue-like behavior in LLC mice is not dependent upon microglial or peripheral macrophage activation. Based on the literature and our data demonstrating attenuation of ubiquitin proteasome pathway activation in the gastrocnemius muscle of Tlr4-/- mice implanted with LLC cells, we interpret our current findings as indication that skeletal muscle TLR4 signaling may be involved. These results are important in that they add to the evidence that tumor-induced fatigue develops independently from classical neuroinflammation.
Collapse
Affiliation(s)
- Elisabeth G. Vichaya
- Department of Psychology & Neuroscience, Baylor University, Waco, TX 76798,Department of Symptom Research, Laboratory of Neuroimmunology, University of Texas MD Anderson Cancer Center, Houston, TX 77030
| | - Bianca G. Ford
- Department of Symptom Research, Laboratory of Neuroimmunology, University of Texas MD Anderson Cancer Center, Houston, TX 77030
| | - Cana B. Quave
- Department of Symptom Research, Laboratory of Neuroimmunology, University of Texas MD Anderson Cancer Center, Houston, TX 77030,University of Texas Health Science Center at Houston, Graduate School of Biomedical Sciences, Houston, TX 77030
| | - M. Raafay Rishi
- Department of Symptom Research, Laboratory of Neuroimmunology, University of Texas MD Anderson Cancer Center, Houston, TX 77030
| | - Aaron J. Grossberg
- Department of Radiation Medicine, Brenden-Colson Center for Pancreatic Care, Cancer Early Detection Advanced Research Center, Oregon Health & Sciences University, Portland, OR, US
| | - Robert Dantzer
- Department of Symptom Research, Laboratory of Neuroimmunology, University of Texas MD Anderson Cancer Center, Houston, TX 77030
| |
Collapse
|
8
|
Grossberg AJ, Vichaya EG, Gross PS, Ford BG, Scott KA, Estrada D, Vermeer DW, Vermeer P, Dantzer R. Interleukin 6-independent metabolic reprogramming as a driver of cancer-related fatigue. Brain Behav Immun 2020; 88:230-241. [PMID: 32428555 PMCID: PMC7415540 DOI: 10.1016/j.bbi.2020.05.043] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/30/2020] [Revised: 05/13/2020] [Accepted: 05/14/2020] [Indexed: 01/08/2023] Open
Abstract
Fatigue is a common and debilitating symptom of cancer with few effective interventions. Cancer-related fatigue (CRF) is often associated with increases in inflammatory cytokines, however inflammation may not be requisite for this symptom, suggesting other biological mediators also play a role. Because tumors are highly metabolically active and can amplify their energetic toll via effects on distant organs, we sought to determine whether CRF could be explained by metabolic competition exacted by the tumor. We used a highly metabolically active murine E6/E7/hRas model of head and neck cancer for this purpose. Mice with or without tumors were submitted to metabolic constraints in the form of voluntary wheel running or acute overnight fasting and their adaptive behavioral (home cage activity and fasting-induced wheel running) and metabolic responses (blood glucose, ketones, and liver metabolic gene expression) were monitored. We found that the addition of running wheel was necessary to measure activity loss, used as a surrogate for fatigue in this study. Tumor-bearing mice engaged in wheel running showed a decrease in blood glucose levels and an increase in lactate accumulation in the skeletal muscle, consistent with inhibition of the Cori cycle. These changes were associated with gene expression changes in the livers consistent with increased glycolysis and suppressed gluconeogenesis. Fasting also decreased blood glucose in tumor-bearing mice, without impairing glucose or insulin tolerance. Fasting-induced increases in wheel running and ketogenesis were suppressed by tumors, which was again associated with a shift from gluconeogenic to glycolytic metabolism in the liver. Blockade of IL-6 signaling with a neutralizing antibody failed to recover any of the behavioral or metabolic outcomes. Taken together, these data indicate that metabolic competition between the tumor and the rest of the organism is an important component of fatigue and support the hypothesis of a central role for IL-6-independent hepatic metabolic reprogramming in the pathophysiology of CRF.
Collapse
Affiliation(s)
- Aaron J Grossberg
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Radiation Medicine, Cancer Early Detection Advanced Research Center, Brenden Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, OR, USA.
| | - Elisabeth G Vichaya
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Psychology and Neuroscience, Baylor University, Waco, TX, USA
| | - Phillip S Gross
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Interdisciplinary Program in Neuroscience, Georgetown University, Washington, DC, USA
| | - Bianca G Ford
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Kiersten A Scott
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Darlene Estrada
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Daniel W Vermeer
- Cancer Biology Research Center, Sanford Research, Sioux Falls, SD, USA
| | - Paola Vermeer
- Cancer Biology Research Center, Sanford Research, Sioux Falls, SD, USA
| | - Robert Dantzer
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| |
Collapse
|
9
|
Eley JG, Chadha AS, Quini C, Vichaya EG, Zhang C, Davis J, Sahoo N, Waddell J, Leiser D, Dilmanian FA, Krishnan S. Pilot study of neurologic toxicity in mice after proton minibeam therapy. Sci Rep 2020; 10:11368. [PMID: 32647361 PMCID: PMC7347840 DOI: 10.1038/s41598-020-68015-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2019] [Accepted: 04/24/2020] [Indexed: 01/03/2023] Open
Abstract
Proton minibeams (MBs) comprised of parallel planar beamlets were evaluated for their ability to spare healthy brain compared to proton broad beams (BBs). Juvenile mice were given partial brain irradiation of 10 or 30 Gy integral dose using 100 MeV protons configured either as BBs or arrays of 0.3-mm planar MBs spaced 1.0 mm apart on center. Neurologic toxicity was evaluated during an 8-month surveillance: no overt constitutional or neurologic dysfunction was noted for any study animals. Less acute epilation was observed in MB than BB mice. Persistent chronic inflammation was noted along the entire BB path in BB mice whereas inflammation was confined to just within the MB peak regions in MB mice. The potential neurologic sparing, possibly via reduced volume of chronic inflammation, offers a compelling rationale for clinical advancement of this proton technique.
Collapse
Affiliation(s)
- John G Eley
- Department of Radiation Oncology, Vanderbilt University School of Medicine, 2220 Pierce Avenue, Preston Research Building B1003, Nashville, TN, 37232, USA.
| | - Awalpreet S Chadha
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
| | - Caio Quini
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
| | - Elisabeth G Vichaya
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
| | - Cancan Zhang
- Department of Radiation Oncology, University of Maryland School of Medicine, 655 West Baltimore Street, Baltimore, MD, 21201, USA
| | - James Davis
- Department of Pathology, Stony Brook Medicine, 101 Nicolls Road, Stony Brook, NY, 11794, USA
| | - Narayan Sahoo
- Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
| | - Jaylyn Waddell
- Department of Pediatrics, University of Maryland School of Medicine, 655 West Baltimore Street, Baltimore, MD, 21201, USA
| | - Dominic Leiser
- Department of Radiation Oncology, University of Maryland School of Medicine, 655 West Baltimore Street, Baltimore, MD, 21201, USA
| | - F Avraham Dilmanian
- Departments of Radiology, Neurology, and Radiation Oncology, Stony Brook Medicine, 101 Nicolls Road, Stony Brook, NY, 11794, USA
| | - Sunil Krishnan
- Department of Radiation Oncology, Mayo Clinic Florida, 4500 San Pablo Road S., Jacksonville, FL, 32224, USA.
| |
Collapse
|
10
|
Vichaya EG, Vermeer DW, Budac D, Lee A, Grossberg A, Vermeer PD, Lee JH, Dantzer R. Inhibition of Indoleamine 2,3 Dioxygenase Does Not Improve Cancer-Related Symptoms in a Murine Model of Human Papilloma Virus-Related Head and Neck Cancer. Int J Tryptophan Res 2019; 12:1178646919872508. [PMID: 31496720 PMCID: PMC6716175 DOI: 10.1177/1178646919872508] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2019] [Accepted: 08/02/2019] [Indexed: 11/15/2022] Open
Abstract
The expression of indoleamine 2,3 dioxygenase (IDO) by tumors can contribute to immunotolerance, and IDO induced by inflammation can also increase risk for the development of behavioral alterations. Thus, this study was initiated to determine whether IDO inhibition, intended to facilitate tumor clearance in response to treatment, attenuates behavioral alterations associated with tumor growth and treatment. We used a murine model of human papilloma virus-related head and neck cancer. We confirmed that tumor cells express IDO and expression was increased by radiotherapy. Interestingly, inhibition of IDO activation by the competitive inhibitor 1-methyl tryptophan mildly exacerbated treatment-associated burrowing deficits (burrowing is a sensitive index of sickness in tumor-bearing mice). Genetic deletion of IDO worsened tumor outcomes and had no effect on the behavioral response as by decreased burrowing or reduced voluntary wheel running. In contrast, oral administration of a specific inhibitor of IDO1 provided no apparent benefit on the tumor response to cancer therapy, yet decreased voluntary wheel-running activity independent of treatment. These results indicate that, independent of its potential effect on tumor clearance, inhibition of IDO does not improve cancer-related symptoms.
Collapse
Affiliation(s)
- Elisabeth G Vichaya
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Daniel W Vermeer
- Cancer Biology Research Center, Sanford Research, Sioux Falls, SD, USA
| | - David Budac
- Neuroinflammation Disease Biology Unit, Lundbeck Research USA, Paramus, NJ, USA
| | - Anna Lee
- Neuroinflammation Disease Biology Unit, Lundbeck Research USA, Paramus, NJ, USA
| | - Aaron Grossberg
- Department of Radiation Medicine, School of Medicine, Oregon Health & Sciences University, Portland, OR, USA
| | - Paola D Vermeer
- Cancer Biology Research Center, Sanford Research, Sioux Falls, SD, USA
| | - John H Lee
- Chan Soon-Shiong Institute for Medicine, El Segundo, CA, USA
| | - Robert Dantzer
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| |
Collapse
|
11
|
Vichaya EG, Laumet G, Christian DL, Grossberg AJ, Estrada DJ, Heijnen CJ, Kavelaars A, Dantzer R. Motivational changes that develop in a mouse model of inflammation-induced depression are independent of indoleamine 2,3 dioxygenase. Neuropsychopharmacology 2019; 44:364-371. [PMID: 29760410 PMCID: PMC6300560 DOI: 10.1038/s41386-018-0075-z] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/02/2018] [Revised: 03/18/2018] [Accepted: 04/16/2018] [Indexed: 12/27/2022]
Abstract
Despite years of research, our understanding of the mechanisms by which inflammation induces depression is still limited. As clinical data points to a strong association between depression and motivational alterations, we sought to (1) characterize the motivational changes that are associated with inflammation in mice, and (2) determine if they depend on inflammation-induced activation of indoleamine 2,3 dioxygenase-1 (IDO1). Lipopolysaccharide (LPS)-treated or spared nerve injured (SNI) wild type (WT) and Ido1-/- mice underwent behavioral tests of antidepressant activity (e.g., forced swim test) and motivated behavior, including assessment of (1) reward expectancy using a food-related anticipatory activity task, (2) willingness to work for reward using a progressive ratio schedule of food reinforcement, (3) effort allocation using a concurrent choice task, and (4) ability to associate environmental cues with reward using conditioned place preference. LPS- and SNI-induced deficits in behavioral tests of antidepressant activity in WT but not Ido1-/- mice. Further, LPS decreased food related-anticipatory activity, reduced performance in the progressive ratio task, and shifted effort toward the preferred reward in the concurrent choice task. These effects were observed in both WT and Ido1-/- mice. Finally, SNI mice developed a conditioned place preference based on relief from pain in an IDO1-independent manner. These findings demonstrate that the motivational effects of inflammation do not require IDO1. Further, they indicate that the motivational component of inflammation-induced depression is mechanistically distinct from that measured by behavioral tests of antidepressant activity.
Collapse
Affiliation(s)
- Elisabeth G. Vichaya
- 0000 0001 2291 4776grid.240145.6Division of Internal Medicine, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA
| | - Geoffroy Laumet
- 0000 0001 2291 4776grid.240145.6Division of Internal Medicine, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA
| | - Diana L. Christian
- 0000 0001 2291 4776grid.240145.6Division of Internal Medicine, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA
| | - Aaron J. Grossberg
- 0000 0001 2291 4776grid.240145.6Division of Internal Medicine, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA
| | - Darlene J. Estrada
- 0000 0001 2291 4776grid.240145.6Division of Internal Medicine, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA
| | - Cobi J. Heijnen
- 0000 0001 2291 4776grid.240145.6Division of Internal Medicine, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA
| | - Annemieke Kavelaars
- 0000 0001 2291 4776grid.240145.6Division of Internal Medicine, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA
| | - Robert Dantzer
- 0000 0001 2291 4776grid.240145.6Division of Internal Medicine, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA
| |
Collapse
|
12
|
Madeo M, Colbert PL, Vermeer DW, Lucido CT, Cain JT, Vichaya EG, Grossberg AJ, Muirhead D, Rickel AP, Hong Z, Zhao J, Weimer JM, Spanos WC, Lee JH, Dantzer R, Vermeer PD. Cancer exosomes induce tumor innervation. Nat Commun 2018; 9:4284. [PMID: 30327461 PMCID: PMC6191452 DOI: 10.1038/s41467-018-06640-0] [Citation(s) in RCA: 150] [Impact Index Per Article: 25.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2017] [Accepted: 09/18/2018] [Indexed: 12/16/2022] Open
Abstract
Patients with densely innervated tumors suffer with increased metastasis and decreased survival as compared to those with less innervated tumors. We hypothesize that in some tumors, nerves are acquired by a tumor-induced process, called axonogenesis. Here, we use PC12 cells as an in vitro neuronal model, human tumor samples and murine in vivo models to test this hypothesis. When appropriately stimulated, PC12 cells extend processes, called neurites. We show that patient tumors release vesicles, called exosomes, which induce PC12 neurite outgrowth. Using a cancer mouse model, we show that tumors compromised in exosome release are less innervated than controls. Moreover, in vivo pharmacological blockade of exosome release similarly attenuates tumor innervation. We characterize these nerves as sensory in nature and demonstrate that axonogenesis is potentiated by the exosome-packaged axonal guidance molecule, EphrinB1. These findings indicate that tumor released exosomes induce tumor innervation and exosomes containing EphrinB1 potentiate this activity.
Collapse
Affiliation(s)
- Marianna Madeo
- Cancer Biology and Immunotherapies Group, Sanford Research, 2301 East 60th St north, Sioux Falls, SD, 57104, USA
| | - Paul L Colbert
- Cancer Biology and Immunotherapies Group, Sanford Research, 2301 East 60th St north, Sioux Falls, SD, 57104, USA
| | - Daniel W Vermeer
- Cancer Biology and Immunotherapies Group, Sanford Research, 2301 East 60th St north, Sioux Falls, SD, 57104, USA
| | - Christopher T Lucido
- Cancer Biology and Immunotherapies Group, Sanford Research, 2301 East 60th St north, Sioux Falls, SD, 57104, USA
| | - Jacob T Cain
- Pediatrics and Rare Diseases Group, Sanford Research, 2301 East 60th St north, Sioux Falls, SD, 57104, USA
| | - Elisabeth G Vichaya
- Department of Symptom Research, MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 384, Houston, TX, 77030, USA
| | - Aaron J Grossberg
- Department of Symptom Research, MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 384, Houston, TX, 77030, USA
- Department of Radiation Medicine, Cancer Early Detection Advanced Research Center, Oregon Health and Science University, 2720 SW Moody Ave KR-CEDR, Portland, OR, 97201, USA
| | - DesiRae Muirhead
- Sanford Health Pathology Clinic, Sanford Health, 1305 West 18th St, Sioux Falls, SD, 57105, USA
| | - Alex P Rickel
- Biomedical Engineering Program, University of South Dakota, 4800 North Career Ave, Sioux Falls, SD, 57107, USA
| | - Zhongkui Hong
- Biomedical Engineering Program, University of South Dakota, 4800 North Career Ave, Sioux Falls, SD, 57107, USA
| | - Jing Zhao
- Population Health Group, Sanford Research, 2301 East 60th St north, Sioux Falls, SD, 57104, USA
| | - Jill M Weimer
- Pediatrics and Rare Diseases Group, Sanford Research, 2301 East 60th St north, Sioux Falls, SD, 57104, USA
| | - William C Spanos
- Cancer Biology and Immunotherapies Group, Sanford Research, 2301 East 60th St north, Sioux Falls, SD, 57104, USA
- Sanford Ears, Nose and Throat, 1310 West 22nd St, Sioux Falls, SD, 57105, USA
| | - John H Lee
- NantKwest, 9920 Jefferson Blvd, Culver City, CA, 90232, USA
| | - Robert Dantzer
- Department of Symptom Research, MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 384, Houston, TX, 77030, USA
| | - Paola D Vermeer
- Cancer Biology and Immunotherapies Group, Sanford Research, 2301 East 60th St north, Sioux Falls, SD, 57104, USA.
| |
Collapse
|
13
|
Lacourt TE, Vichaya EG, Escalante C, Manzullo EF, Gunn B, Hess KR, Heijnen CJ, Dantzer R. An effort expenditure perspective on cancer-related fatigue. Psychoneuroendocrinology 2018; 96:109-117. [PMID: 29929087 PMCID: PMC6131045 DOI: 10.1016/j.psyneuen.2018.06.009] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/11/2017] [Revised: 04/16/2018] [Accepted: 06/08/2018] [Indexed: 12/20/2022]
Abstract
While fatigue is the most common and debilitating side effect of cancer and cancer treatment it is still poorly understood, partly because it is usually characterized by patient-reported outcomes. As patient-reports are inherently subjective, behavioral correlates of the symptom of fatigue are needed to increase our understanding of the symptom. We focused on motivational effort expenditure as a crucial behavior in cancer-related fatigue, using a validated computerized task contrasting high effort/high reward and low effort/low reward choices under different probabilities of success. Effort expenditure-choices were analyzed in 47 cancer patients differing by their status; current evidence for disease (n = 17) or post-treatment survivors with no evidence for disease (n = 30). In addition, patient-reported fatigue, negative and positive affect, and biomarkers of inflammation were assessed. Patient-reported general and motivational fatigue, negative affect, and plasma concentrations of pro-inflammatory biomarkers were related to higher effort expenditure while positive affect was associated with lower effort expenditure. As all four measures interacted with patient status, exploratory models were computed for patients and survivors separately. These analyses indicated that the effects of fatigue and negative affect were predominantly seen in survivors. In patients still under or shortly post treatment, general fatigue, but not motivational fatigue, was associated with lower effort expenditure but only in the most favorable reward condition. Negative affect did not have an effect. Thus, the effects observed seemed primarily driven by cancer survivors in whom both fatigue and negative affect were associated with higher effort expenditure. These findings are tentatively interpreted to suggest that a tendency to invest more effort despite feelings of fatigue is a vulnerability for developing chronic fatigue. Inflammation and negative affect might contribute to fatigue in some survivors through this effort investment pathway.
Collapse
Affiliation(s)
- Tamara E Lacourt
- Neuroimmunology Laboratory, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
| | - Elisabeth G Vichaya
- Neuroimmunology Laboratory, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Carmen Escalante
- Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Ellen F Manzullo
- Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Brandon Gunn
- Radiation Oncology Department, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Kenneth R Hess
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Cobi J Heijnen
- Neuroimmunology Laboratory, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Robert Dantzer
- Neuroimmunology Laboratory, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| |
Collapse
|
14
|
Abstract
Inflammation can profoundly impact motivated behavior, as is the case with inflammation-induced depression. By evaluating objectively measurable basic neurobehavioral processes involved in motivation, recent research indicates that inflammation generally reduces approach motivation and enhances avoidance motivation. Increased effort valuation largely mediates the effects of inflammation on approach motivation. Changes in reward valuation are not uniformly observed in approach motivation. However, inflammation increases the averseness of negative stimuli. Within the context of both approach and avoidance motivation, inflammation appears to enhance the contrast between concurrently presented stimuli. While changes in both approach and avoidance motivation appear to be mediated by midbrain dopaminergic neurotransmission to the ventral striatum, it is unclear if the enhanced contrast is mediated by the same system.
Collapse
Affiliation(s)
- Elisabeth G. Vichaya
- Division of Internal Medicine, Department of Symptom Research,
University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 384,
Houston, TX 77030, USA
| | - Robert Dantzer
- Division of Internal Medicine, Department of Symptom Research,
University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 384,
Houston, TX 77030, USA
| |
Collapse
|
15
|
Lacourt TE, Vichaya EG, Chiu GS, Dantzer R, Heijnen CJ. The High Costs of Low-Grade Inflammation: Persistent Fatigue as a Consequence of Reduced Cellular-Energy Availability and Non-adaptive Energy Expenditure. Front Behav Neurosci 2018; 12:78. [PMID: 29755330 PMCID: PMC5932180 DOI: 10.3389/fnbeh.2018.00078] [Citation(s) in RCA: 88] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2017] [Accepted: 04/09/2018] [Indexed: 02/03/2023] Open
Abstract
Chronic or persistent fatigue is a common, debilitating symptom of several diseases. Persistent fatigue has been associated with low-grade inflammation in several models of fatigue, including cancer-related fatigue and chronic fatigue syndrome. However, it is unclear how low-grade inflammation leads to the experience of fatigue. We here propose a model of an imbalance in energy availability and energy expenditure as a consequence of low-grade inflammation. In this narrative review, we discuss how chronic low-grade inflammation can lead to reduced cellular-energy availability. Low-grade inflammation induces a metabolic switch from energy-efficient oxidative phosphorylation to fast-acting, but less efficient, aerobic glycolytic energy production; increases reactive oxygen species; and reduces insulin sensitivity. These effects result in reduced glucose availability and, thereby, reduced cellular energy. In addition, emerging evidence suggests that chronic low-grade inflammation is associated with increased willingness to exert effort under specific circumstances. Circadian-rhythm changes and sleep disturbances might mediate the effects of inflammation on cellular-energy availability and non-adaptive energy expenditure. In the second part of the review, we present evidence for these metabolic pathways in models of persistent fatigue, focusing on chronic fatigue syndrome and cancer-related fatigue. Most evidence for reduced cellular-energy availability in relation to fatigue comes from studies on chronic fatigue syndrome. While the mechanistic evidence from the cancer-related fatigue literature is still limited, the sparse results point to reduced cellular-energy availability as well. There is also mounting evidence that behavioral-energy expenditure exceeds the reduced cellular-energy availability in patients with persistent fatigue. This suggests that an inability to adjust energy expenditure to available resources might be one mechanism underlying persistent fatigue.
Collapse
|
16
|
Grossberg AJ, Vichaya EG, Christian DL, Molkentine JM, Vermeer DW, Gross PS, Vermeer PD, Lee JH, Dantzer R. Tumor-Associated Fatigue in Cancer Patients Develops Independently of IL1 Signaling. Cancer Res 2017; 78:695-705. [PMID: 29217760 DOI: 10.1158/0008-5472.can-17-2168] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2017] [Revised: 10/20/2017] [Accepted: 11/27/2017] [Indexed: 12/19/2022]
Abstract
Fatigue is the most common symptom of cancer at diagnosis, yet causes and effective treatments remain elusive. As tumors can be highly inflammatory, it is generally accepted that inflammation mediates cancer-related fatigue. However, evidence to support this assertion is mostly correlational. In this study, we directly tested the hypothesis that fatigue results from propagation of tumor-induced inflammation to the brain and activation of the central proinflammatory cytokine, IL1. The heterotopic syngeneic murine head and neck cancer model (mEER) caused systemic inflammation and increased expression of Il1b in the brain while inducing fatigue-like behaviors characterized by decreased voluntary wheel running and exploratory activity. Expression of Il1b in the brain was not associated with any alterations in motivation, measured by responding in a progressive ratio schedule of food reinforcement, depression-like behaviors, or energy balance. Decreased wheel running occurred prior to Il1b detection in the brain, when systemic inflammation was minimal. Furthermore, mice null for two components of IL1β signaling, the type 1 IL1 receptor or the receptor adapter protein MyD88, were not protected from tumor-induced decreases in wheel running, despite attenuated cytokine action and expression. Behavioral and inflammatory analysis of four additional syngeneic tumor models revealed that tumors can induce fatigue regardless of their systemic or central nervous system inflammatory potential. Together, our results show that brain IL1 signaling is not necessary for tumor-related fatigue, dissociating this type of cancer sequela from systemic cytokine expression.Significance: These findings challenge the current understanding of fatigue in cancer patients, the most common and debilitating sequela associated with malignancy. Cancer Res; 78(3); 695-705. ©2017 AACR.
Collapse
Affiliation(s)
- Aaron J Grossberg
- Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas. .,Department of Symptom Research, MD Anderson Cancer Center, Houston, Texas
| | | | - Diana L Christian
- Department of Symptom Research, MD Anderson Cancer Center, Houston, Texas
| | - Jessica M Molkentine
- Department of Experimental Radiation Oncology, MD Anderson Cancer Center, Houston, Texas
| | - Daniel W Vermeer
- Cancer Biology Research Center, Sanford Research, Sioux Falls, South Dakota
| | - Phillip S Gross
- Department of Symptom Research, MD Anderson Cancer Center, Houston, Texas
| | - Paola D Vermeer
- Cancer Biology Research Center, Sanford Research, Sioux Falls, South Dakota
| | - John H Lee
- Cancer Biology Research Center, Sanford Research, Sioux Falls, South Dakota
| | - Robert Dantzer
- Department of Symptom Research, MD Anderson Cancer Center, Houston, Texas
| |
Collapse
|
17
|
Vichaya EG, Vermeer DW, Christian DL, Molkentine JM, Mason KA, Lee JH, Dantzer R. Neuroimmune mechanisms of behavioral alterations in a syngeneic murine model of human papilloma virus-related head and neck cancer. Psychoneuroendocrinology 2017; 79:59-66. [PMID: 28259044 PMCID: PMC5402618 DOI: 10.1016/j.psyneuen.2017.02.006] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/04/2016] [Revised: 01/10/2017] [Accepted: 02/07/2017] [Indexed: 12/30/2022]
Abstract
Patients with cancer often experience a high symptom burden prior to the start of treatment. As disease- and treatment-related neurotoxicities appear to be additive, targeting disease-related symptoms may attenuate overall symptom burden for cancer patients and improve the tolerability of treatment. It has been hypothesized that disease-related symptoms are a consequence of tumor-induced inflammation. We tested this hypothesis using a syngeneic heterotopic murine model of human papilloma virus (HPV)-related head and neck cancer. This model has the advantage of being mildly aggressive and not causing cachexia or weight loss. We previously showed that this tumor leads to increased IL-6, IL-1β, and TNF-α expression in the liver and increased IL-1β expression in the brain. The current study confirmed these features and demonstrated that the tumor itself exhibits high inflammatory cytokine expression (e.g., IL-6, IL-1β, and TNF-α) compared to healthy tissue. While there is a clear relationship between cytokine levels and behavioral deficits in this model, the behavioral changes are surprisingly mild. Therefore, we sought to confirm the relationship between behavior and inflammation by amplifying the effect using a low dose of lipopolysaccharide (LPS, 0.1mg/kg). In tumor-bearing mice LPS induced deficits in nest building, tail suspension, and locomotor activity approximately 24h after LPS. However, these mice did not display an exacerbation of LPS-induced weight loss, anorexia, or anhedonia. Further, while heightened serum IL-6 was observed there was minimal priming of liver or brain cytokine expression. Next we sought to inhibit tumor-induced burrowing deficits by reducing inflammation using minocycline. Minocycline (∼50mg/kg/day in drinking water) was able to attenuate tumor-induced inflammation and burrowing deficits. These data provide evidence in favor of an inflammatory-like mechanism for the behavioral alterations associated with tumor growth in a syngeneic murine model of HPV-related head and neck cancer. However, the inflammatory state and behavioral changes induced by this tumor clearly differ from other forms of inflammation-induced sickness behavior.
Collapse
Affiliation(s)
- Elisabeth G. Vichaya
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 384, Houston, TX, 77030, USA,Corresponding author: Elisabeth G. Vichaya, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Hoclomb Blvd, Unit 384, Houston, TX 77030, Phone: 832-750-1557,
| | - Daniel W. Vermeer
- Cancer Biology Research Center, Sanford Research, 2301 E. 60th St N, Sioux Falls, SD, 57104, USA
| | - Diana L. Christian
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 384, Houston, TX, 77030, USA
| | - Jessica M. Molkentine
- Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 66, Houston, TX, 77030, USA
| | - Kathy A. Mason
- Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 66, Houston, TX, 77030, USA
| | - John H. Lee
- Cancer Biology Research Center, Sanford Research, 2301 E. 60th St N, Sioux Falls, SD, 57104, USA,Chan Soon Shiong Institute of Molecular Medicine, 9920 Jefferson Blvd, Culver City, CA 90230, USA
| | - Robert Dantzer
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 384, Houston, TX, 77030, USA
| |
Collapse
|
18
|
Chiu GS, Maj MA, Rizvi S, Dantzer R, Vichaya EG, Laumet G, Kavelaars A, Heijnen CJ. Pifithrin-μ Prevents Cisplatin-Induced Chemobrain by Preserving Neuronal Mitochondrial Function. Cancer Res 2016; 77:742-752. [PMID: 27879267 DOI: 10.1158/0008-5472.can-16-1817] [Citation(s) in RCA: 78] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2016] [Revised: 10/06/2016] [Accepted: 11/04/2016] [Indexed: 01/21/2023]
Abstract
Cognitive impairment, termed chemobrain, is a common neurotoxicity associated with chemotherapy treatment, affecting an estimated 78% of patients. Prompted by the hypothesis that neuronal mitochondrial dysfunction underlies chemotherapy-induced cognitive impairment (CICI), we explored the efficacy of administering the small-molecule pifithrin (PFT)-μ, an inhibitor of mitochondrial p53 accumulation, in preventing CICI. Male C57BL/6J mice injected with cisplatin ± PFT-μ for two 5-day cycles were assessed for cognitive function using novel object/place recognition and alternation in a Y-maze. Cisplatin impaired performance in the novel object/place recognition and Y-maze tests. PFT-μ treatment prevented CICI and associated cisplatin-induced changes in coherency of myelin basic protein fibers in the cingular cortex and loss of doublecortin+ cells in the subventricular zone and hippocampal dentate gyrus. Mechanistically, cisplatin decreased spare respirator capacity of brain synaptosomes and caused abnormal mitochondrial morphology, which was counteracted by PFT-μ administration. Notably, increased mitochondrial p53 did not lead to cerebral caspase-3 activation or cytochrome-c release. Furthermore, PFT-μ administration did not impair the anticancer efficacy of cisplatin and radiotherapy in tumor-bearing mice. Our results supported the hypothesis that neuronal mitochondrial dysfunction induced by mitochondrial p53 accumulation is an underlying cause of CICI and that PFT-μ may offer a tractable therapeutic strategy to limit this common side-effect of many types of chemotherapy. Cancer Res; 77(3); 742-52. ©2016 AACR.
Collapse
Affiliation(s)
- Gabriel S Chiu
- Laboratory of Neuroimmunology, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Magdalena A Maj
- Laboratory of Neuroimmunology, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Sahar Rizvi
- Laboratory of Neuroimmunology, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Robert Dantzer
- Laboratory of Neuroimmunology, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Elisabeth G Vichaya
- Laboratory of Neuroimmunology, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Geoffroy Laumet
- Laboratory of Neuroimmunology, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Annemieke Kavelaars
- Laboratory of Neuroimmunology, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Cobi J Heijnen
- Laboratory of Neuroimmunology, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.
| |
Collapse
|
19
|
Vichaya EG, Molkentine JM, Vermeer DW, Walker AK, Feng R, Holder G, Luu K, Mason RM, Saligan L, Heijnen CJ, Kavelaars A, Mason KA, Lee JH, Dantzer R. Sickness behavior induced by cisplatin chemotherapy and radiotherapy in a murine head and neck cancer model is associated with altered mitochondrial gene expression. Behav Brain Res 2015; 297:241-50. [PMID: 26475509 DOI: 10.1016/j.bbr.2015.10.024] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2015] [Revised: 10/05/2015] [Accepted: 10/08/2015] [Indexed: 11/28/2022]
Abstract
The present study was undertaken to explore the possible mechanisms of the behavioral alterations that develop in response to cancer and to cancer therapy. For this purpose we used a syngeneic heterotopic mouse model of human papilloma virus (HPV)-related head and neck cancer in which cancer therapy is curative. Mice implanted or not with HPV+ tumor cells were exposed to sham treatment or a regimen of cisplatin and radiotherapy (chemoradiation). Sickness was measured by body weight loss and reduced food intake. Motivation was measured by burrowing, a highly prevalent species specific behavior. Tumor-bearing mice showed a gradual decrease in burrowing over time and increased brain and liver inflammatory cytokine mRNA expression by 28 days post tumor implantation. Chemoradiation administered to healthy mice resulted in a mild decrease in burrowing, body weight, and food intake. Chemoradiation in tumor-bearing mice decreased tumor growth and abrogated liver and brain inflammation, but failed to attenuate burrowing deficits. PCR array analysis of selected hypoxia and mitochondrial genes revealed that both the tumor and chemoradiation altered the expression of genes involved in mitochondrial energy metabolism within the liver and brain and increased expression of genes related to HIF-1α signaling within the brain. The most prominent changes in brain mitochondrial genes were noted in tumor-bearing mice treated with chemoradiation. These findings indicate that targeting mitochondrial dysfunction following cancer and cancer therapy may be a strategy for prevention of cancer-related symptoms.
Collapse
Affiliation(s)
- Elisabeth G Vichaya
- Department of Symptom Research, MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 384, Houston, TX 77030, United States.
| | - Jessica M Molkentine
- Department of Experimental Radiation Oncology, MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 66, Houston, TX 77030, United States
| | - Daniel W Vermeer
- Cancer Biology Research Center, Sanford Research, 2301 E. 60th St. N., Sioux Falls, SD 57104, United States
| | - Adam K Walker
- Department of Symptom Research, MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 384, Houston, TX 77030, United States
| | - Rebekah Feng
- National Institute of Nursing Research, Building 3, Room 5E14, 3 Center Dr., Bethesda, MD 20892, United States
| | - Gerard Holder
- National Institute of Nursing Research, Building 3, Room 5E14, 3 Center Dr., Bethesda, MD 20892, United States
| | - Katherine Luu
- Department of Symptom Research, MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 384, Houston, TX 77030, United States
| | - Ryan M Mason
- Department of Experimental Radiation Oncology, MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 66, Houston, TX 77030, United States
| | - Leo Saligan
- National Institute of Nursing Research, Building 3, Room 5E14, 3 Center Dr., Bethesda, MD 20892, United States
| | - Cobi J Heijnen
- Department of Symptom Research, MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 384, Houston, TX 77030, United States
| | - Annemieke Kavelaars
- Department of Symptom Research, MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 384, Houston, TX 77030, United States
| | - Kathy A Mason
- Department of Experimental Radiation Oncology, MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 66, Houston, TX 77030, United States
| | - John H Lee
- Cancer Biology Research Center, Sanford Research, 2301 E. 60th St. N., Sioux Falls, SD 57104, United States
| | - Robert Dantzer
- Department of Symptom Research, MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 384, Houston, TX 77030, United States
| |
Collapse
|
20
|
Linsenbardt HR, Cook JL, Young EE, Vichaya EG, Young CR, Reusser NM, Storts R, Welsh CJ, Meagher MW. Social disruption alters pain and cognition in an animal model of multiple sclerosis. J Neuroimmunol 2015; 288:56-68. [PMID: 26531695 DOI: 10.1016/j.jneuroim.2015.09.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2015] [Revised: 09/09/2015] [Accepted: 09/10/2015] [Indexed: 01/29/2023]
Abstract
Although pain and cognitive deficits are widespread and debilitating symptoms of multiple sclerosis (MS), they remain poorly understood. Theiler's murine encephalomyelitis virus (TMEV) infection is an animal model of MS where disease course is exacerbated by prior stressors. Here chronic infection coupled with prior social stress increased pain behavior and impaired hippocampal-dependent memory consolidation during the demyelinating phase of disease in SJL mice. These results suggest that the TMEV model may be useful in investigating pain and cognitive impairments in MS. However, in contrast to prior Balb/cJ studies, stress failed to consistently alter behavioral and physiological indicators of disease course.
Collapse
Affiliation(s)
- H R Linsenbardt
- Department of Psychology, Texas A&M University, College Station, TX, United States; Texas A&M Institute for Neuroscience, Texas A&M University, College Station, TX, United States
| | - J L Cook
- Department of Psychology, Texas A&M University, College Station, TX, United States
| | - E E Young
- Department of Psychology, Texas A&M University, College Station, TX, United States
| | - E G Vichaya
- Department of Psychology, Texas A&M University, College Station, TX, United States
| | - C R Young
- Department of Veterinary Integrative Biosciences, Texas A&M University, College Station, TX, United States
| | - N M Reusser
- Department of Psychology, Texas A&M University, College Station, TX, United States
| | - R Storts
- Department of Veterinary Pathobiology, Texas A&M University, College Station, TX, United States
| | - C J Welsh
- Texas A&M Institute for Neuroscience, Texas A&M University, College Station, TX, United States; Department of Veterinary Integrative Biosciences, Texas A&M University, College Station, TX, United States
| | - M W Meagher
- Department of Psychology, Texas A&M University, College Station, TX, United States; Texas A&M Institute for Neuroscience, Texas A&M University, College Station, TX, United States.
| |
Collapse
|
21
|
Mendoza TR, Wang XS, Williams LA, Shi Q, Vichaya EG, Dougherty PM, Thomas SK, Yucel E, Bastida CC, Woodruff JF, Cleeland CS. Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment Scale. J Pain 2015. [PMID: 26210041 DOI: 10.1016/j.jpain.2015.07.002] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
UNLABELLED Various sensory and motor effects are associated with cancer treatment-induced peripheral neuropathy. The current method for capturing the multifaceted nature of neuropathy includes a combination of objective tests, clinician evaluation, and subjective patient report, an approach that is often not logistically feasible, especially for multisite trials. We report the performance of a brief yet comprehensive, easily administered measure, the Treatment-Induced Neuropathy Assessment Scale (TNAS), for assessing the severity and course of neuropathy across various cancer treatments. Data were derived from 4 longitudinal or cross-sectional patient cohorts (N = 573). Patients with multiple myeloma treated primarily with bortezomib and patients with colorectal cancer receiving oxaliplatin evaluated candidate items. Cognitive debriefing showed that all items were easy to understand, and this preliminary TNAS demonstrated reliability, validity, and sensitivity. Numbness/tingling was the most severe item, regardless of therapeutic agent. Although numbness and general pain were moderately correlated, patients perceived them as distinct. Most TNAS items were more severe at follow-up, demonstrating the sensitivity of the instrument to accumulating dose. The TNAS will be refined with further patient input, with final psychometric evaluation conducted in a new patient sample receiving treatments known to be associated with peripheral neuropathy. The nonpainful component of neuropathy may be more disabling than the pain component. PERSPECTIVE Our data suggest that the nonpainful components of neuropathy may be more disabling than the pain component during cancer treatment. Here we report data on sensory and motor symptoms reported by patients receiving neurotoxic cancer therapy, and we detail the development of a neuropathy assessment scale that follows regulatory guidance for patient-reported outcomes.
Collapse
Affiliation(s)
- Tito R Mendoza
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.
| | - Xin Shelley Wang
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Loretta A Williams
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Qiuling Shi
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Elisabeth G Vichaya
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Patrick M Dougherty
- Department of Pain Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Sheeba K Thomas
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Emre Yucel
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Christel C Bastida
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Jeanie F Woodruff
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Charles S Cleeland
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas
| |
Collapse
|
22
|
Vichaya EG, Chiu GS, Krukowski K, Lacourt TE, Kavelaars A, Dantzer R, Heijnen CJ, Walker AK. Mechanisms of chemotherapy-induced behavioral toxicities. Front Neurosci 2015; 9:131. [PMID: 25954147 PMCID: PMC4404721 DOI: 10.3389/fnins.2015.00131] [Citation(s) in RCA: 118] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2014] [Accepted: 04/01/2015] [Indexed: 11/13/2022] Open
Abstract
While chemotherapeutic agents have yielded relative success in the treatment of cancer, patients are often plagued with unwanted and even debilitating side-effects from the treatment which can lead to dose reduction or even cessation of treatment. Common side effects (symptoms) of chemotherapy include (i) cognitive deficiencies such as problems with attention, memory and executive functioning; (ii) fatigue and motivational deficit; and (iii) neuropathy. These symptoms often develop during treatment but can remain even after cessation of chemotherapy, severely impacting long-term quality of life. Little is known about the underlying mechanisms responsible for the development of these behavioral toxicities, however, neuroinflammation is widely considered to be one of the major mechanisms responsible for chemotherapy-induced symptoms. Here, we critically assess what is known in regards to the role of neuroinflammation in chemotherapy-induced symptoms. We also argue that, based on the available evidence, neuroinflammation is unlikely the only mechanism involved in the pathogenesis of chemotherapy-induced behavioral toxicities. We evaluate two other putative candidate mechanisms. To this end we discuss the mediating role of damage-associated molecular patterns (DAMPs) activated in response to chemotherapy-induced cellular damage. We also review the literature with respect to possible alternative mechanisms such as a chemotherapy-induced change in the bioenergetic status of the tissue involving changes in mitochondrial function in relation to chemotherapy-induced behavioral toxicities. Understanding the mechanisms that underlie the emergence of fatigue, neuropathy, and cognitive difficulties is vital to better treatment and long-term survival of cancer patients.
Collapse
Affiliation(s)
- Elisabeth G Vichaya
- Laboratory of Neuroimmunology, Division of Internal Medicine, Department of Symptom Research, The University of Texas MD Anderson Cancer Center Houston, TX, USA
| | - Gabriel S Chiu
- Laboratory of Neuroimmunology, Division of Internal Medicine, Department of Symptom Research, The University of Texas MD Anderson Cancer Center Houston, TX, USA
| | - Karen Krukowski
- Laboratory of Neuroimmunology, Division of Internal Medicine, Department of Symptom Research, The University of Texas MD Anderson Cancer Center Houston, TX, USA
| | - Tamara E Lacourt
- Laboratory of Neuroimmunology, Division of Internal Medicine, Department of Symptom Research, The University of Texas MD Anderson Cancer Center Houston, TX, USA
| | - Annemieke Kavelaars
- Laboratory of Neuroimmunology, Division of Internal Medicine, Department of Symptom Research, The University of Texas MD Anderson Cancer Center Houston, TX, USA
| | - Robert Dantzer
- Laboratory of Neuroimmunology, Division of Internal Medicine, Department of Symptom Research, The University of Texas MD Anderson Cancer Center Houston, TX, USA
| | - Cobi J Heijnen
- Laboratory of Neuroimmunology, Division of Internal Medicine, Department of Symptom Research, The University of Texas MD Anderson Cancer Center Houston, TX, USA
| | - Adam K Walker
- Laboratory of Neuroimmunology, Division of Internal Medicine, Department of Symptom Research, The University of Texas MD Anderson Cancer Center Houston, TX, USA
| |
Collapse
|
23
|
Vichaya EG, Hunt SC, Dantzer R. Lipopolysaccharide reduces incentive motivation while boosting preference for high reward in mice. Neuropsychopharmacology 2014; 39:2884-90. [PMID: 24917202 PMCID: PMC4200499 DOI: 10.1038/npp.2014.141] [Citation(s) in RCA: 60] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/16/2013] [Revised: 05/14/2013] [Accepted: 06/05/2014] [Indexed: 12/20/2022]
Abstract
Inflammation has been implicated in the development of various psychiatric disorders, including depression. However, the neurobehavioral mechanism involved in this relationship remains elusive. This gap in knowledge may best be filled by evaluating elementary neurobehavioral units affected by inflammation rather than behavioral changes in conventional animal tests of depression. To this end, the current study used a concurrent choice paradigm to evaluate inflammation-induced motivational changes. Male C57BL/6J mice (n=27) were food restricted to between 85 and 90% of their free-feeding weight and were trained to perform a concurrent choice task where they nose-poked for grain rewards on a fixed ratio (FR) 1 schedule (low effort/low reward) and chocolate-flavored rewards on a FR-10 schedule (high effort/high reward). A counterbalanced-within subjects design was used. A single intraperitoneal injection of 0.33 mg/kg lipopolysaccharide (LPS) was used to induce peripheral inflammation. Twenty-four hours after LPS administration, mice showed a reduction in the total number of nose pokes. A proportionally greater reduction in nose pokes was observed for grain, resulting in an increase in percent chocolate pellets earned. These behavioral changes cannot be explained by reduced appetite as feeding before the test led to a similar increase in percent chocolate pellets earned but without any decrease in responding. These results indicate that inflammation modulates incentive motivation by affecting willingness to exert effort for reward and not by reducing sensitivity to reward.
Collapse
Affiliation(s)
- Elisabeth G Vichaya
- Division of Internal Medicine, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Sarah C Hunt
- Division of Internal Medicine, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Robert Dantzer
- Division of Internal Medicine, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,Division of Internal Medicine, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1400 Pressler Road Unit 1450, Houston, TX 77030, USA, Tel: +1 713 563 4793, Fax: +1 713 745 3475, E-mail:
| |
Collapse
|
24
|
Kosturakis AK, He Z, Li Y, Boyette-Davis JA, Shah N, Thomas SK, Zhang H, Vichaya EG, Wang XS, Wendelschafer-Crabb G, Kennedy WR, Simone DA, Cleeland CS, Dougherty PM. Subclinical peripheral neuropathy in patients with multiple myeloma before chemotherapy is correlated with decreased fingertip innervation density. J Clin Oncol 2014; 32:3156-62. [PMID: 25154818 DOI: 10.1200/jco.2013.54.5418] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE The goal in this study was to determine the incidence of subclinical neuropathy in treatment-naive patients with multiple myeloma (MM) with no history of peripheral neuropathy using quantitative sensory tests (QSTs) and its correlation with innervation density of the extremities using noninvasive laser reflectance confocal microscopy. PATIENTS AND METHODS QST results were collected for 27 patients with a diagnosis of MM and compared with data collected from 30 age- and sex-matched healthy volunteers. Skin temperature, sensorimotor function (grooved pegboard test), and detection thresholds for temperature, sharpness, and low-threshold mechanical stimuli (von Frey monofilaments and bumps detection test) were measured. Meissner's corpuscle (MC) density in the fingertips was assessed using in vivo laser reflectance confocal microscopy. RESULTS Patients showed a high incidence (> 80%) of ≥ one subclinical QST deficit. These included increased von Frey, bumps, and warmth detection thresholds as compared with healthy volunteers. Patients also showed increases in cold pain, sensorimotor deficits (grooved pegboard test), and higher overall neuropathy scores. MC density was significantly lower in patients than controls and showed significant inverse correlation with bumps detection threshold. CONCLUSION Patients with MM commonly present with sensory and sensorimotor deficits before undergoing treatment, and these deficits seem to result from disease-related decreases in peripheral innervation density.
Collapse
Affiliation(s)
- Alyssa K Kosturakis
- Alyssa K. Kosturakis, Zijing He, Yan Li, Nina Shah, Sheeba K. Thomas, Haijun Zhang, Elisabeth G. Vichaya, Xin Shelley Wang, Charles S. Cleeland, and Patrick M. Dougherty, University of Texas MD Anderson Cancer Center, Houston, TX; Jessica A. Boyette-Davis, York College, York, PA; Gwen Wendelschafer-Crabb and William R. Kennedy, University of Minnesota School of Medicine; and Donald A. Simone, University of Minnesota School of Dentistry, Minneapolis, MN
| | - Zijing He
- Alyssa K. Kosturakis, Zijing He, Yan Li, Nina Shah, Sheeba K. Thomas, Haijun Zhang, Elisabeth G. Vichaya, Xin Shelley Wang, Charles S. Cleeland, and Patrick M. Dougherty, University of Texas MD Anderson Cancer Center, Houston, TX; Jessica A. Boyette-Davis, York College, York, PA; Gwen Wendelschafer-Crabb and William R. Kennedy, University of Minnesota School of Medicine; and Donald A. Simone, University of Minnesota School of Dentistry, Minneapolis, MN
| | - Yan Li
- Alyssa K. Kosturakis, Zijing He, Yan Li, Nina Shah, Sheeba K. Thomas, Haijun Zhang, Elisabeth G. Vichaya, Xin Shelley Wang, Charles S. Cleeland, and Patrick M. Dougherty, University of Texas MD Anderson Cancer Center, Houston, TX; Jessica A. Boyette-Davis, York College, York, PA; Gwen Wendelschafer-Crabb and William R. Kennedy, University of Minnesota School of Medicine; and Donald A. Simone, University of Minnesota School of Dentistry, Minneapolis, MN
| | - Jessica A Boyette-Davis
- Alyssa K. Kosturakis, Zijing He, Yan Li, Nina Shah, Sheeba K. Thomas, Haijun Zhang, Elisabeth G. Vichaya, Xin Shelley Wang, Charles S. Cleeland, and Patrick M. Dougherty, University of Texas MD Anderson Cancer Center, Houston, TX; Jessica A. Boyette-Davis, York College, York, PA; Gwen Wendelschafer-Crabb and William R. Kennedy, University of Minnesota School of Medicine; and Donald A. Simone, University of Minnesota School of Dentistry, Minneapolis, MN
| | - Nina Shah
- Alyssa K. Kosturakis, Zijing He, Yan Li, Nina Shah, Sheeba K. Thomas, Haijun Zhang, Elisabeth G. Vichaya, Xin Shelley Wang, Charles S. Cleeland, and Patrick M. Dougherty, University of Texas MD Anderson Cancer Center, Houston, TX; Jessica A. Boyette-Davis, York College, York, PA; Gwen Wendelschafer-Crabb and William R. Kennedy, University of Minnesota School of Medicine; and Donald A. Simone, University of Minnesota School of Dentistry, Minneapolis, MN
| | - Sheeba K Thomas
- Alyssa K. Kosturakis, Zijing He, Yan Li, Nina Shah, Sheeba K. Thomas, Haijun Zhang, Elisabeth G. Vichaya, Xin Shelley Wang, Charles S. Cleeland, and Patrick M. Dougherty, University of Texas MD Anderson Cancer Center, Houston, TX; Jessica A. Boyette-Davis, York College, York, PA; Gwen Wendelschafer-Crabb and William R. Kennedy, University of Minnesota School of Medicine; and Donald A. Simone, University of Minnesota School of Dentistry, Minneapolis, MN
| | - Haijun Zhang
- Alyssa K. Kosturakis, Zijing He, Yan Li, Nina Shah, Sheeba K. Thomas, Haijun Zhang, Elisabeth G. Vichaya, Xin Shelley Wang, Charles S. Cleeland, and Patrick M. Dougherty, University of Texas MD Anderson Cancer Center, Houston, TX; Jessica A. Boyette-Davis, York College, York, PA; Gwen Wendelschafer-Crabb and William R. Kennedy, University of Minnesota School of Medicine; and Donald A. Simone, University of Minnesota School of Dentistry, Minneapolis, MN
| | - Elisabeth G Vichaya
- Alyssa K. Kosturakis, Zijing He, Yan Li, Nina Shah, Sheeba K. Thomas, Haijun Zhang, Elisabeth G. Vichaya, Xin Shelley Wang, Charles S. Cleeland, and Patrick M. Dougherty, University of Texas MD Anderson Cancer Center, Houston, TX; Jessica A. Boyette-Davis, York College, York, PA; Gwen Wendelschafer-Crabb and William R. Kennedy, University of Minnesota School of Medicine; and Donald A. Simone, University of Minnesota School of Dentistry, Minneapolis, MN
| | - Xin Shelley Wang
- Alyssa K. Kosturakis, Zijing He, Yan Li, Nina Shah, Sheeba K. Thomas, Haijun Zhang, Elisabeth G. Vichaya, Xin Shelley Wang, Charles S. Cleeland, and Patrick M. Dougherty, University of Texas MD Anderson Cancer Center, Houston, TX; Jessica A. Boyette-Davis, York College, York, PA; Gwen Wendelschafer-Crabb and William R. Kennedy, University of Minnesota School of Medicine; and Donald A. Simone, University of Minnesota School of Dentistry, Minneapolis, MN
| | - Gwen Wendelschafer-Crabb
- Alyssa K. Kosturakis, Zijing He, Yan Li, Nina Shah, Sheeba K. Thomas, Haijun Zhang, Elisabeth G. Vichaya, Xin Shelley Wang, Charles S. Cleeland, and Patrick M. Dougherty, University of Texas MD Anderson Cancer Center, Houston, TX; Jessica A. Boyette-Davis, York College, York, PA; Gwen Wendelschafer-Crabb and William R. Kennedy, University of Minnesota School of Medicine; and Donald A. Simone, University of Minnesota School of Dentistry, Minneapolis, MN
| | - William R Kennedy
- Alyssa K. Kosturakis, Zijing He, Yan Li, Nina Shah, Sheeba K. Thomas, Haijun Zhang, Elisabeth G. Vichaya, Xin Shelley Wang, Charles S. Cleeland, and Patrick M. Dougherty, University of Texas MD Anderson Cancer Center, Houston, TX; Jessica A. Boyette-Davis, York College, York, PA; Gwen Wendelschafer-Crabb and William R. Kennedy, University of Minnesota School of Medicine; and Donald A. Simone, University of Minnesota School of Dentistry, Minneapolis, MN
| | - Donald A Simone
- Alyssa K. Kosturakis, Zijing He, Yan Li, Nina Shah, Sheeba K. Thomas, Haijun Zhang, Elisabeth G. Vichaya, Xin Shelley Wang, Charles S. Cleeland, and Patrick M. Dougherty, University of Texas MD Anderson Cancer Center, Houston, TX; Jessica A. Boyette-Davis, York College, York, PA; Gwen Wendelschafer-Crabb and William R. Kennedy, University of Minnesota School of Medicine; and Donald A. Simone, University of Minnesota School of Dentistry, Minneapolis, MN
| | - Charles S Cleeland
- Alyssa K. Kosturakis, Zijing He, Yan Li, Nina Shah, Sheeba K. Thomas, Haijun Zhang, Elisabeth G. Vichaya, Xin Shelley Wang, Charles S. Cleeland, and Patrick M. Dougherty, University of Texas MD Anderson Cancer Center, Houston, TX; Jessica A. Boyette-Davis, York College, York, PA; Gwen Wendelschafer-Crabb and William R. Kennedy, University of Minnesota School of Medicine; and Donald A. Simone, University of Minnesota School of Dentistry, Minneapolis, MN
| | - Patrick M Dougherty
- Alyssa K. Kosturakis, Zijing He, Yan Li, Nina Shah, Sheeba K. Thomas, Haijun Zhang, Elisabeth G. Vichaya, Xin Shelley Wang, Charles S. Cleeland, and Patrick M. Dougherty, University of Texas MD Anderson Cancer Center, Houston, TX; Jessica A. Boyette-Davis, York College, York, PA; Gwen Wendelschafer-Crabb and William R. Kennedy, University of Minnesota School of Medicine; and Donald A. Simone, University of Minnesota School of Dentistry, Minneapolis, MN.
| |
Collapse
|
25
|
Jones D, Vichaya EG, Cleeland CS, Cohen L, Thekdi SM, Wang XS, Fisch MJ. Screening for depressed mood in patients with cancer using the MD Anderson Symptom Inventory: investigation of a practical approach for the oncologist. J Oncol Pract 2013; 10:e95-102. [PMID: 24281151 DOI: 10.1200/jop.2013.001112] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
PURPOSE Depression is a significant concern in outpatient oncology care, yet clinicians face practical challenges in accurately and efficiently screening patients for it. This study investigated whether a single item or multiple items from an existing multisymptom scale, the MD Anderson Symptom Inventory (MDASI), might serve as effective initial screens for depressed mood. METHODS Data were collected from two cohorts of patients. Cohort 1 comprised 187 patients with non-small-cell lung cancer who completed the Beck Depression Inventory II; cohort 2 comprised 281 patients with renal cell carcinoma who completed the Center for Epidemiologic Studies Depression Scale. All patients completed the MDASI. Single-item and multiple-item MDASI solutions were identified using cohort 1 and validated in cohort 2. Sensitivity and specificity of the solutions were assessed through binary linear regression; cut points were identified using receiver operating characteristic analysis. RESULTS The MDASI single item "sadness" was the best solution identified in cohort 1 for screening for depressed mood relative to other affective items (distress, enjoyment of life, mood). At a cut point ≥ 4 (0 to 10 scale), the "sadness" item exhibited a clinically acceptable specificity of 81.5%, sensitivity of 72.0%, a negative predictive value of 95.0%, and a positive predictive value of 37.5%. This solution was successfully validated in cohort 2. CONCLUSION The MDASI "sadness" item has modest sensitivity and high negative predictive value and can serve as a useful initial screen for depressed mood. This approach may improve the efficiency and acceptability of depression screening for both clinicians and patients.
Collapse
Affiliation(s)
- Desiree Jones
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | | | | | | | | |
Collapse
|
26
|
Jones D, Vichaya EG, Wang XS, Sailors MH, Cleeland CS, Wefel JS. Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. Cancer 2013; 119:4188-95. [PMID: 24105672 DOI: 10.1002/cncr.28323] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2013] [Revised: 06/21/2013] [Accepted: 07/23/2013] [Indexed: 12/22/2022]
Abstract
BACKGROUND Few studies have examined the acute effects of autologous hematopoietic stem cell transplantation (Au-HSCT) on the neuropsychological functioning of patients with multiple myeloma (MM). The prevalence of cognitive deficits after induction chemotherapy (pre-AuHSCT) was examined in patients with MM, clinically significant changes in cognitive function 1 and 3 months post-AuHSCT were determined, and patients who may be vulnerable to cognitive decline during this period were identified. METHODS A total of 53 patients with MM were recruited pre-AuHSCT. Neuropsychological tests measuring multiple cognitive domains (attention, psychomotor speed, learning/memory, language, executive function, motor function) were administered pre-AuHSCT and 1 and 3 months post-AuHSCT. A pretreatment assessment was not available. An Overall Cognitive Function Index was computed to determine cognitive impairment pre-AuHSCT, and a practice-effect-adjusted Reliable Change Index was used to determine cognitive change over time. RESULTS Overall, deficits were more frequent in learning/memory, executive function, motor function, and psychomotor speed. Before AuHSCT, 47% of patients (25/53) exhibited cognitive impairment as determined by the Overall Cognitive Function Index. One month post-AuHSCT, 49% of patients (20/41) demonstrated clinically significant decline on 1 or more measures; 3 months post-AuHSCT, 48% (14 of 29 patients) showed decline on 1 or more measures. Older patients, minorities, and those with advanced disease, more induction cycles, or postinduction deficits showed greater vulnerability to decline. CONCLUSIONS Nearly half of the patients showed vulnerability to impairment in learning/memory or executive function after receiving induction therapy, and the prevalence of impairment remained high post-AuHSCT. Awareness of cognitive impairment and associated risk factors in actively treated patients is important for considering psychosocial or other support for patients with acute cognitive symptoms.
Collapse
Affiliation(s)
- Desiree Jones
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | | | | | | | | | | |
Collapse
|
27
|
Jones D, Vichaya EG, Wang XS, Williams LA, Shah ND, Thomas SK, Johnson VE, Champlin RE, Cleeland CS, Mendoza TR. Validation of the M. D. Anderson Symptom Inventory multiple myeloma module. J Hematol Oncol 2013; 6:13. [PMID: 23384030 PMCID: PMC3598689 DOI: 10.1186/1756-8722-6-13] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2012] [Accepted: 01/31/2013] [Indexed: 11/12/2022] Open
Abstract
Background The symptom burden associated with multiple myeloma (MM) is often severe. Presently, no instrument comprehensively assesses disease-related and treatment-related symptoms in patients with MM. We sought to validate a module of the M. D. Anderson Symptom Inventory (MDASI) developed specifically for patients with MM (MDASI-MM). Methods The MDASI-MM was developed with clinician input, cognitive debriefing, and literature review, and administered to 132 patients undergoing induction chemotherapy or stem cell transplantation. We demonstrated the MDASI-MM’s reliability (Cronbach α values); criterion validity (item and subscale correlations between the MDASI-MM and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the EORTC MM module (QLQ-MY20)), and construct validity (differences between groups by performance status). Ratings from transplant patients were examined to demonstrate the MDASI-MM’s sensitivity in detecting the acute worsening of symptoms post-transplantation. Results The MDASI-MM demonstrated excellent correlations with subscales of the 2 EORTC instruments, strong ability to distinguish clinically different patient groups, high sensitivity in detecting change in patients’ performance status, and high reliability. Cognitive debriefing confirmed that the MDASI-MM encompasses the breadth of symptoms relevant to patients with MM. Conclusion The MDASI-MM is a valid, reliable, comprehensive-yet-concise tool that is recommended as a uniform symptom assessment instrument for patients with MM.
Collapse
Affiliation(s)
- Desiree Jones
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1450, 77030, Houston, TX 77030, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Thomas SK, Mendoza TR, Vichaya EG, Wang XS, Sailors MH, Williams LA, Dougherty PM, Cleeland CS. Validation of the chemotherapy-induced neuropathy assessment scale. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.9140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9140 Background: Many of the assessment tools used to assess peripheral neuropathy in clinical trials focus on painful neuropathy. However, some chemotherapy agents cause both painful and non-painful peripheral neuropathy. The Chemotherapy-Induced Neuropathy Assessment Scale (CINAS) was designed to evaluate the multi-dimensional nature of chemotherapy-induced neuropathy, including non-painful sensory and motor deficits. This study evaluated the psychometric properties of the CINAS in patients with multiple myeloma (MM) receiving induction chemotherapy and/or autologous hematopoietic stem cell transplantation. Methods: We collected demographic and clinical data and administered 2 items measuring pain and numbness/tingling at its worst (0-10 scale), and the CINAS. A total CINAS score was computed by summing all 11 CINAS items. For reliability and validity analyses, we used the highest total CINAS score for each patient. Validity was assessed by factor analysis and by correlating CINAS subscales with the pain and numbness/tingling items. Cronbach alpha reliability coefficients were computed. To test sensitivity, we compared change in total CINAS score during induction from baseline to last total CINAS score in a subset of patients (N=20) receiving bortezomib or thalidomide. We hypothesized that such patients would develop neuropathy. Results: Ninety patients were enrolled. Participants were primarily white (90%) and male (63%). Factor analysis revealed 3 underlying constructs for the CINAS - sensory, motor functioning, and allodynia - explaining 74% of the common variance. Cronbach alphas were 0.84, 0.85, and 0.83 for the sensory, motor functioning, and allodynia subscales, respectively, while subscale correlations with the numbness/tingling item were 0.74, 0.56, and 0.52, respectively. Pain was only modestly correlated with these subscales (0.21, 0.36, 0.29). Total CINAS scores of patients receiving bortezomib or thalidomide induction worsened significantly (from 3.4 to 11.9, effect size=0.55, p<.02). Conclusions: The CINAS demonstrated validity, reliability and sensitivity in patients with MM during and after chemotherapy and can be used to assess the multidimensional aspects of chemotherapy-induced neuropathy.
Collapse
Affiliation(s)
| | - Tito R. Mendoza
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | | | | | - Mary H Sailors
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | | | | | | |
Collapse
|
29
|
Vichaya EG, Wang XS, Boyette-Davis JA, He Z, Thomas SK, Shah N, Mendoza TR, Williams LA, Cleeland CS, Dougherty PM. Baseline subclinical sensory deficits and the development of pain and numbness in patients with multiple myeloma (MM) being treated with chemotherapy. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.9082] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9082 Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting toxicity experienced by patients with MM. Patients may develop painful and non-painful (e.g., numbness) symptoms that impair function and often persist after therapy is terminated. This study examined the predictive value of baseline subclinical sensory deficits on the development of treatment-related pain and numbness. Methods: Patients (N=56) who had two or fewer cycles of induction therapy and no obvious neuropathy were assessed for sensory deficits using quantitative sensory testing (QST). Patients reported the severity of pain and numbness (on a 0-10 scale) at least weekly via the MD Anderson Symptom Inventory during induction (up to 16 weeks); 15 of 56 patients provided data for up to 16 additional weeks of maintenance therapy. These values correlate to patient reported pain and numbness in the hands/feet. Based on data collected from healthy controls, patients were classified as being with or without a sensory deficit at baseline on each QST domain. We fit linear mixed models for pain and numbness with each sensory deficit and time, controlling for cumulative cycles, diabetes, age, and treatment agent. Data is shown as mean ± standard deviation. Results: Patients who showed baseline deficits in sharpness detection (20%) reported significantly lower levels of pain (1.2±1.9 vs 3.1±2.9, p=.004) and numbness (0.4±0.8 vs 2.4±2.6, p<.001) during induction therapy and less numbness (0.0 vs 3.5±2.8, p=.001) during maintenance therapy. Further, those who showed deficits in warmth detection (40%) reported higher levels of pain (5.2±2.8 vs 1.7±2.3, p<.001) and numbness (5.8±2.2 vs 1.6±1.8, p<.001) during maintenance therapy. Finally, those with lower skin temperature (47%) reported higher levels of pain (4.5±2.3 vs 1.7±2.9, p=.005) during maintenance therapy. Conclusions: Our results suggest that subclinical sensory deficits may be useful in determining a patient’s risk for developing CIPN prior to initiation of induction therapy. This information could be used to provide patients with more-personalized chemotherapy plans that take into account their neuropathy risk.
Collapse
Affiliation(s)
| | | | | | - Zijing He
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | | | - Nina Shah
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - Tito R. Mendoza
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | | | | | | |
Collapse
|
30
|
Jones D, Vichaya EG, Wang XS, Mendoza TR, Mobley GM, Lu C, Cleeland CS. Disease-driven symptoms and response to chemotherapy in treatment-naive patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.9118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9118 Background: The disease-driven symptoms of treatment-naïve patients with advanced NSCLC have not been the primary focus of previous studies. One reason for this gap in the literature is that randomized trials typically lack an opportunity to capture the symptom profiles of patients who are truly treatment-naïve. To address this need, this study sought to: (i) characterize the symptom profile of treatment-naïve patients with advanced NSCLC, and (ii) describe patients’ response to chemotherapy. Methods: The study sampleconsisted of43 treatment-naïve patients (no prior treatment by surgery, radiation, or chemotherapy) with a primary diagnosis of advanced NSCLC from the MD Anderson Cancer Center, and was derived from a larger study (Cleeland et al. J Clin Oncol 29:2859-65, 2011). Patients’ symptoms were assessed pre-chemotherapy, and then prospectively at 6, 12, and 18 weeks from initiation of chemotherapy using the MD Anderson Symptom Inventory Lung Cancer module. Results: The top symptoms reported by patients, in order of severity, were shortness of breath, fatigue, distress, sadness, drowsiness, and pain. Chemotherapy did not significantly improve shortness of breath, drowsiness, pain, disturbed sleep, lack of appetite, coughing, and constipation in this sample of patients, and was associated with a significant increase in levels of fatigue and numbness (mean difference in fatigue at 12 weeks from baseline = 2.8; 95% CI, 0.5–2.9; p = .01; and in numbness from baseline = 1.1; 95% CI, 0.2–2.0; p = .02). Conclusions: This study characterizes the disease-driven symptoms of truly treatment-naïve patients with advanced NSCLC. Knowledge of these symptoms is of intrinsic value in the clinical management of advanced NSCLC as it provides the critical reference point against which symptom palliation must be measured. Patients’ lack of symptomatic improvement from chemotherapy in this study suggests that this sub-set of patients may have had rapidly progressing disease and that chemotherapy may have prevented symptoms levels from worsening. Consistent with literature, transient but significant increase in both fatigue and numbness are chemotherapy-related toxicities.
Collapse
Affiliation(s)
- Desiree Jones
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | | | | | - Tito R. Mendoza
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - Gary M. Mobley
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - Charles Lu
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | | |
Collapse
|
31
|
Shah N, Jones D, Mendoza TR, Williams LA, Wang XS, Vichaya EG, Sailors MH, Champlin RE, Cleeland CS. Validation of the M. D. Anderson Symptom Inventory multiple myeloma module. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.6551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6551 Background: Validated scales exist for quality of life assessment in patients with multiple myeloma (MM); however, no existing tool comprehensively assesses disease- and treatment-related symptoms in these patients. The aim of this study was to validate a module of the M. D. Anderson Symptom Inventory developed for patients with MM (MDASI-MM). The MDASI-MM includes 13 core symptoms, 6 interference items, and 7 MM-specific items: constipation, muscle weakness, diarrhea, sore mouth/throat, rash, difficulty concentrating, and bone aches. Methods: The MDASI-MM was administered to 2 cohorts of patients with MM. The first cohort (N=86) consisted of cross-sectional symptom data from patients at the beginning of induction chemotherapy or autologous hematopoietic stem cell transplant (HSCT). This cohort was used to demonstrate i) known-group validity, by detecting differences in groups by performance status; ii) concurrent validity, by correlating selected items and subscales from the MDASI-MM with those from the Short Form Health Survey (SF-12) and the EORTC-QLQC30; and iii) reliability, by computing Cronbach alpha values. The second cohort (N=53) consisted of symptom data collected at 2 points: prior to transplant and 7 days post-HSCT. This cohort was used to demonstrate the sensitivity of the MDASI-MM to detect acute worsening of patients’ symptoms post-HSCT. Results: The MDASI-MM detected significant differences in symptoms and interference levels according to patients’ performance status (P < .001). MDASI-MM scores correlated with those from SF-12 subscales for physical, emotional, cognitive, and social functioning (all P <.001) and with comparable items from the EORTC-QLQC30 (such as pain, fatigue, difficulty concentrating, constipation, and diarrhea, all P < .001). Cronbach alphas were 0.85 for symptom severity and 0.87 for interference. The MDASI-MM’s overall mean scores worsened between pre- and post-HSCT (1.32 vs. 2.55 (range = 0-10), P < .001). Conclusions: The MDASI-MM is a valid, reliable, and concise tool that can be used to quantitatively assess symptom severity and interference in clinical trials and care of MM patients.
Collapse
Affiliation(s)
- Nina Shah
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - Desiree Jones
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - Tito R. Mendoza
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | | | | | | | - Mary H Sailors
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | | | | |
Collapse
|
32
|
Vichaya EG, Young EE, Frazier MA, Cook JL, Welsh CJ, Meagher MW. Social disruption induced priming of CNS inflammatory response to Theiler's virus is dependent upon stress induced IL-6 release. J Neuroimmunol 2011; 239:44-52. [PMID: 22000153 DOI: 10.1016/j.jneuroim.2011.08.006] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2011] [Revised: 07/17/2011] [Accepted: 08/10/2011] [Indexed: 01/09/2023]
Abstract
Chronic social disruption stress (SDR) exacerbates acute and chronic phase Theiler's murine encephalomyelitis virus (TMEV) infection, a mouse model of multiple sclerosis. However, the precise mechanism by which this occurs remains unknown. The present study suggests that SDR exacerbates TMEV disease course by priming virus-induced neuroinflammation. It was demonstrated that IL-1β mRNA expression increases following acute SDR; however, IL-6 mRNA expression, but not IL-1β, is upregulated in response to chronic SDR. Furthermore, this study demonstrated SDR prior to infection increases infection related central IL-6 and IL-1β mRNA expression, and administration of IL-6 neutralizing antibody during SDR reverses this increase in neuroinflammation.
Collapse
Affiliation(s)
- E G Vichaya
- Dept. of Psychology, College of Liberal Arts, Texas A&M University, United States
| | | | | | | | | | | |
Collapse
|
33
|
Young EE, Sieve AN, Vichaya EG, Carcoba LM, Young CR, Ambrus A, Storts R, Welsh CJR, Meagher MW. Chronic restraint stress during early Theiler's virus infection exacerbates the subsequent demyelinating disease in SJL mice: II. CNS disease severity. J Neuroimmunol 2010; 220:79-89. [PMID: 20167380 PMCID: PMC2856483 DOI: 10.1016/j.jneuroim.2010.01.015] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2009] [Revised: 01/22/2010] [Accepted: 01/22/2010] [Indexed: 12/20/2022]
Abstract
Theiler's murine encephalomyelitis virus (TMEV) infection is a well-characterized model of multiple sclerosis (MS). Previous research has shown that chronic restraint stress (RS) during early TMEV infection exacerbates behavioral signs of the disease. The present data suggest that RS-induced increases in CNS inflammation, demyelination, and axonal degeneration may underlie this exacerbation. In addition, we report that males exhibit greater CNS inflammation and higher numbers of demyelinating lesions while females show greater susceptibility to RS-induced exacerbation. These findings indicate that RS during early TMEV infection increases CNS lesion formation during the late phase and suggest that the effects of RS are sex-dependent.
Collapse
MESH Headings
- Animals
- Axons/immunology
- Axons/pathology
- Axons/virology
- Cardiovirus Infections/immunology
- Cardiovirus Infections/physiopathology
- Central Nervous System/immunology
- Central Nervous System/pathology
- Central Nervous System/virology
- Chronic Disease
- Demyelinating Autoimmune Diseases, CNS/immunology
- Demyelinating Autoimmune Diseases, CNS/physiopathology
- Demyelinating Autoimmune Diseases, CNS/virology
- Disease Models, Animal
- Disease Progression
- Encephalomyelitis/immunology
- Encephalomyelitis/physiopathology
- Encephalomyelitis/virology
- Female
- Male
- Mice
- Nerve Fibers, Myelinated/immunology
- Nerve Fibers, Myelinated/pathology
- Nerve Fibers, Myelinated/virology
- Restraint, Physical/adverse effects
- Restraint, Physical/psychology
- Severity of Illness Index
- Sex Characteristics
- Stress, Psychological/immunology
- Stress, Psychological/physiopathology
- Theilovirus/immunology
- Wallerian Degeneration/immunology
- Wallerian Degeneration/pathology
- Wallerian Degeneration/virology
Collapse
Affiliation(s)
- Erin E Young
- Department of Psychology, College of Liberal Arts, Texas A&M University College Station, TX 77843, United States.
| | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Vichaya EG, Baumbauer KM, Carcoba LM, Grau JW, Meagher MW. Spinal glia modulate both adaptive and pathological processes. Brain Behav Immun 2009; 23:969-76. [PMID: 19435601 PMCID: PMC2749915 DOI: 10.1016/j.bbi.2009.05.001] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/12/2009] [Revised: 05/05/2009] [Accepted: 05/05/2009] [Indexed: 12/16/2022] Open
Abstract
Recent research indicates that glial cells control complex functions within the nervous system. For example, it has been shown that glial cells contribute to the development of pathological pain, the process of long-term potentiation, and the formation of memories. These data suggest that glial cell activation exerts both adaptive and pathological effects within the CNS. To extend this line of work, the present study investigated the role of glia in spinal learning and spinal learning deficits using the spinal instrumental learning paradigm. In this paradigm rats are transected at the second thoracic vertebra (T2) and given shock to one hind limb whenever the limb is extended (controllable shock). Over time these subjects exhibit an increase in flexion duration that reduces net shock exposure. However, when spinalized rats are exposed to uncontrollable shock or inflammatory stimuli prior to testing with controllable shock, they exhibit a learning deficit. To examine the role of glial in this paradigm, spinal glial cells were pharmacologically inhibited through the use of fluorocitrate. Our results indicate that glia are involved in the acquisition, but not maintenance, of spinal learning. Furthermore, the data indicate that glial cells are involved in the development of both shock and inflammation-induced learning deficits. These findings are consistent with prior research indicating that glial cells are involved in both adaptive and pathological processes within the spinal cord.
Collapse
Affiliation(s)
| | | | | | | | - Mary W. Meagher
- Corresponding Author: Mary W. Meagher, Texas A&M University, MS 4235, College Station, TX 77843, , Phone: 979-845-2564, Fax: 979-458-4727
| |
Collapse
|
35
|
Grimes JS, Creech SK, Young EE, Vichaya EG, Meagher MW. Distraction speeds the decay of shock-induced hypoalgesia: evidence for the contribution of memory systems in affective pain modulation. J Pain 2008; 10:282-92. [PMID: 19070552 DOI: 10.1016/j.jpain.2008.09.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/26/2008] [Revised: 09/09/2008] [Accepted: 09/12/2008] [Indexed: 11/28/2022]
Abstract
UNLABELLED Previous research indicates that exposure to shock decreases thermal pain sensitivity in humans. This hypoalgesia has been attributed to a centrally mediated fear state that activates descending inhibitory pathways. Animal research suggests that distraction alters the activation of these hypoalgesic systems. To determine whether the pain memory alters the activation of hypoalgesic systems in humans, the present study examined whether a post-shock distractor attenuates shock-induced hypoalgesia. If fear-inducing shocks are represented by a limited capacity working memory system, then a distractor should speed the decay of the hypoalgesia. Healthy men were randomly assigned to 1 of 4 groups: shock-distraction, shock-no distraction, no shock-distraction, and no shock-no distraction. Following baseline pain tests, participants in the shock groups were presented with 3 brief shocks. Immediately following shock, an unexpected vibration stimulus was presented to participants in the distraction groups. Both self-report and physiological (SCL, HR) measures indicated that shock exposure resulted in fear, arousal, and decreased pain sensitivity. Consistent with prior animal studies, presentation of a post-shock distractor sped the decay of shock-induced hypoalgesia. Specifically, the distraction group exhibited significantly less shock-induced hypoalgesia compared to the no-distraction group. These findings provide additional evidence for the involvement of memory processes in the activation of descending pain inhibitory pathways. PERSPECTIVE This study demonstrated that the presentation of a distracting stimulus immediately following 3 brief shocks attenuated shock-induced hypoalgesia in healthy human subjects. Understanding the impact of post-pain distraction on pain processing may have important clinical implications because it may influence patients' willingness to undergo future painful medical procedures.
Collapse
Affiliation(s)
- Jeffrey S Grimes
- Department of Psychology, Texas A & M University, College Station, Texas 77843-4235, USA
| | | | | | | | | |
Collapse
|
36
|
Meagher MW, Johnson RR, Young EE, Vichaya EG, Lunt S, Hardin EA, Connor MA, Welsh CJR. Interleukin-6 as a mechanism for the adverse effects of social stress on acute Theiler's virus infection. Brain Behav Immun 2007; 21:1083-95. [PMID: 17591434 PMCID: PMC2538675 DOI: 10.1016/j.bbi.2007.05.001] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/26/2006] [Revised: 05/02/2007] [Accepted: 05/04/2007] [Indexed: 12/29/2022] Open
Abstract
Prior exposure to social disruption stress (SDR) exacerbates both the acute and chronic phase of Theiler's murine encephalomyelitis virus infection (TMEV; [Johnson, R.R., Storts, R., Welsh, T.H., Jr., Welsh, C.J., Meagher, M.W., 2004. Social stress alters the severity of acute Theiler's virus infection. J. Neuroimmunol. 148, 74--85; Johnson, R.R., Prentice, T.W., Bridegam, P., Young, C.R., Steelman, A.J., Welsh, T.H., Welsh, C.J.R., Meagher, M.W., 2006. Social stress alters the severity and onset of the chronic phase of Theiler's virus infection. J. Neuroimmunol. 175, 39--51]). However, the neuroimmune mechanism(s) mediating this effect have not been determined. The present study examined whether stress-induced increases in the proinflammatory cytokine interleukin-6 (IL-6) contributes to the adverse effects of SDR on acute TMEV infection. Experiment 1 demonstrated that SDR increases central and peripheral levels of IL-6 and that this effect is reversed by intracerebral ventricular infusion of neutralizing antibody to IL-6 prior to each of six SDR sessions. Although SDR reduced the sensitivity of spleen cells to the anti-inflammatory effects of corticosterone, the neutralizing antibody to IL-6 did not alter this effect. To investigate whether stress-induced increases in IL-6 contribute to the exacerbation of acute TMEV infection, Experiment 2 examined whether intracerebral administration of neutralizing antibody to IL-6 during SDR would prevent the subsequent exacerbation of acute TMEV infection. Experiment 3 then replaced the social stress with intracerebral infusion of IL-6 to assess sufficiency. As expected, prior exposure to SDR subsequently increased infection-related sickness behaviors, motor impairment, CNS viral titers, and CNS inflammation. These deleterious effects of SDR were either prevented or significantly attenuated by intracerebral infusion of neutralizing antibody to IL-6 during the stress exposure period. However, infusion of IL-6 alone did not mimic the adverse effects of SDR. We conclude that IL-6 is necessary but not sufficient to exacerbate acute TMEV infection.
Collapse
Affiliation(s)
- Mary W Meagher
- Department of Psychology, College of Liberal Arts, Texas A&M University, College Station, TX 77843-4235, USA.
| | | | | | | | | | | | | | | |
Collapse
|